| Name | Title | Contact Details |
|---|
Otava is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MASA Medical Transportation Solutions is a company that provides emergency medical transportation services and protection from high emergency medical transportation costs.
Polyvue Technologies is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
IOA is committed to providing solutions that improve healthcare spaces. We listen to our customers in order to design, develop and engineer innovations that meet unfulfilled needs while inspiring great Design. A family-owned company, the Delmestri family has been manufacturing furniture for four generations. The company was founded in Udine, Northern Italy in 1924, and was known as a leading manufacturer of contemporary seating designs.
Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.